THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...

The FDA granted breakthrough status to Serial CTRS, an AI tool that improves survival predictions in non–small cell lung ...

Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a ...

Non-small-cell lung cancer (NSCLC) is the most common type of cancer affecting the lungs. The diverse types of NSCLC are characterized by cancer cells that grow and spread in different ways.

EGFR-TKI 已成为 EGFR 突变晚期非小细胞肺癌（NSCLC）患者的标准治疗方案[1]，然而，约 2%~5% 的初治 EGFR 突变晚期 NSCLC 患者合并原发 MET 扩增，且接受 EGFR-TKI ...

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for 80 to 85% of all cases of lung cancer. There are different stages of NSCLC, ranging from 0 to 4; ...

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...

PROVIDENCE, RI - Ocean Biomedical (NASDAQ: OCEA) has announced research findings that show its immunotherapy candidates can work synergistically with tyrosine kinase inhibitors (TKIs), potentially ...

A new case report details a novel genetic mutation linked to drug resistance in a non-small cell lung cancer patient ...

CStone Pharma announces inclusion of Cejemly as a first-line combination therapy for NSCLC in ESMO guideline: Suzhou, China Tuesday, February 11, 2025, 13:00 Hrs [IST] CStone Phar ...

Heather Wakelee, MD, Stanford University, discusses the pros and cons of different durations of immunotherapy in non-small cell lung cancer (NSCLC) and the future outlook for patient-specific care.